Mesenchymal stem cells are originally thought of as bone marrow derived, adherent cells, that have the ability to differentiate into a variety of tissues. Initial studies demonstrated that mesenchymal stem cells can differentiate into bone, cartilage, fat and muscle. These cells possess a very strong possibility for commercialization and therapeutics development since they can be administered...
This patent covers the composition of matter for the myofibrillogenesis-inducing RNA (MIR) molecule. MIR appears to be important for myofibrillogenesis (a stage in cardiogenesis) in a type of salamander called the Mexican axolotl. Since the claims cover composition of matter for a molecule found on a non-human species, it will be...
This patent covers the use of the gastrin related peptide receptor (GRP receptor) as a marker of embryonic stem cell differentiation. Essentially when embryonic stem cells differentiate they start to downregulate expression of GRP receptor. This assay is useful for knowing the state of differentiation of embryonic stem cells. Since Geron is anticipating to enter...
This patent has three main areas covered in its claims:
1. Induction of new kidney tissue growth.
2. Induction of kidney morphogenesis.
3. Repair of kidney tissue.
These are performed by administration of appropriate concentrations of the following proteins: OP-1, OP-2, BMP-2, BMP-4, BMP-5,
This patent covers the use of medium obtained from the supernatant of cultured hippocampal neurons for use in the induction of neural differentiation of stem cells. The stem cells that can be differentiated into neurons by culture in the media include: - Embryonic stem cells - Embryonic germ cells - Embryonic carcinoma - Bone marrow stromal cells - Bone marrow hematopoietic...
This patent covers a pharmaceutical agent, and numerous derivatives thereof, for manipulation of cellular and stem cell activity. The family of compounds covered are called phthalazinediones, and they have previously been described to possess various anti-inflammatory activities. The patent claims include methods of treatment for metabolic diseases and methods of decreasing metabolic...
This patent teaches ways of modulating "stress" in cells through administration of "therapeutically effective amount of a phthalazine dione" in its one independent claim. The Assignee company, Bach Pharma, Inc is currently practicing the patent in the form of a registered drug (in Russia), Galavit® whose chemically active substance is Monosodium 5-Amino...
The patent describes a simple method of inducing differentiation of bone marrow into islets by a simple two step culture approach involving an initial culture in low concentration of glucose (at least 3 days) followed by a subsequent culture in high concentration of glucose (at least 7 days). The resulting cells generate insulin in response to sugar, and are capable of preventing...
This is a composition of matter patent on a series of compounds capable of inducing generation of bone tissue by inducing maturation of bone precursor cells and/or inducing transdifferentiation. The examples section shows that treating mesenchymal stem cells in vitro with the compounds induces formation of osteocytes, as well as synergy with certain members of the bone morphogenic protein...
There are numerous ways to maintain embryonic stem cells in culture proliferating and not to lose their differentiation ability. For example, Novocell, Geron, and WARF have issued patents on various approaches to this problem. But perhaps equally, if not more, important is the question...